Compare FGBI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | CRDL |
|---|---|---|
| Founded | 1934 | 2017 |
| Country | United States | Canada |
| Employees | 346 | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 132.6M |
| IPO Year | N/A | 2017 |
| Metric | FGBI | CRDL |
|---|---|---|
| Price | $10.81 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 22.5K | ★ 334.6K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $0.88 |
| 52 Week High | $11.02 | $1.71 |
| Indicator | FGBI | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 34.33 |
| Support Level | $7.98 | $0.93 |
| Resistance Level | N/A | $1.09 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 75.66 | 16.33 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.